ArticleEuropean journal of pediatrics2025
Usefulness of urinary β2-microglobulin for diagnosing acute focal bacterial nephritis.
Article in European journal of pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this study, we aimed to evaluate the usefulness of urinary β2-microglobulin (U-β2MG) for diagnosing acute focal bacterial nephritis (AFBN) among upper urinary tract infections (UTIs). This retrospective study was performed at a single institution and included patients younger than 16 years of age diagnosed with upper UTIs. Patients were divided into the AFBN group and acute pyelonephritis (APN) group. Levels of U-β2MG corrected using urinary creatinine (U-β2MG/Ucre) were compared between groups. A multiple regression analysis was performed using Log(U-β2MG/Ucre) as a dependent factor and the diagnosis (AFBN or APN), age, sex, hydronephrosis grade, urinary pH, and fever interval before admission as independent factors. To discriminate AFBN and APN, thresholds of U-β2MG/Ucre and C-reactive protein (CRP) levels were measured using the receiver-operating characteristic curve. Nineteen patients and 37 patients with AFBN and APN, respectively, were analyzed. The U-β2MG/Ucre level differed significantly between the AFBN and APN groups (10762 μg/gCr vs. 1525 μg/gCr, respectively; P = 0.007). The multiple regression analysis indicated that the Log(U-β2MG/Ucre) value of the AFBN group was considerably higher than that of the APN group (P = 0.004). The threshold values of U-β2MG/Ucre and CRP levels were 2070 μg/gCr and 5.7 mg/dL, respectively. Sensitivity and specificity were 0.95 and 0.68, respectively, when both thresholds were used.Conclusions: The U-β2MG/Ucre level of patients with AFBN was significantly higher than that of patients with APN. Therefore, U-β2MG/Ucre could be used to discriminate between AFBN and APN. What is Known: • U-β2MG can aid in discriminating between upper and lower UTIs; however, using both U-β2MG and procalcitonin allows for more accurate differentiation What is New: • U-β2MG may be useful for discriminating between AFBN and APN in upper UTIs. Assessing both U-β2MG and CRP levels may improve the diagnosis of AFBN without invasive imaging tests.
Indexed as
Identifiers
40172724What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.